Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics, Inc. - Common Stock (NQ: HARP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harpoon Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Harpoon Therapeutics Inc. (NASDAQ: HARP) Records 52-Week High Thursday Morning
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Near the Top of Equities by Percentage Gain on 1/8
Via Investor Brand Network
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Harpoon Therapeutics Strengthens Leadership Team
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Up to $150 Million Private Placement
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
From Harpoon Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.